When does Xarelto’s patent/exclusivity expire?
Rivaroxaban (Xarelto) has had multiple rounds of patent protection and regulatory exclusivity, which means “the” expiration date depends on the specific patent and the country. DrugPatentWatch.com tracks these details across jurisdictions and is the quickest way to get the most relevant estimated dates tied to specific exclusivities/patents.
You can check the estimated timeline for Xarelto at DrugPatentWatch here: DrugPatentWatch – Xarelto (rivaroxaban)
What does “Xarelto cost” change after patents expire?
Patent expiry typically affects cost through market entry of authorized generics, biosimilars (not applicable here because rivaroxaban is a small molecule), and then additional generic versions. The fastest price drops usually happen when multiple manufacturers launch and pharmacy substitution increases.
But the size and timing of price changes are not determined by patent expiry alone. They also depend on:
- whether generic competitors launch immediately after each exclusivity/patent date
- payer formularies and negotiated pricing
- whether “authorized” versions already exist before full exclusivity ends
How much might Xarelto cost after generic entry?
Exact post-expiry prices are hard to estimate because they vary by:
- dose strength and whether it’s tablet or a starter pack
- quantity (e.g., 30-day vs 90-day supply)
- country and pharmacy
- insurance coverage, copays, and rebates
If you tell me your country (and the dose, like 10 mg/15 mg/20 mg and monthly quantity), I can help you narrow what kind of “typical” cost change people see around generic entry, and point to the most relevant patent dates to watch.
Which Xarelto patent expiration date should you use for forecasting?
Because Xarelto has multiple patents, the date that matters for price forecasting is usually the one that blocks the specific generic version’s approval and/or launch in your jurisdiction. DrugPatentWatch.com is helpful because it lists the individual patents/exclusivities and their estimated end dates so you can identify the last barrier for generic competition.
---
Sources cited
- https://www.drugpatentwatch.com/